Biodentin

Phase 3Small molecule

UUniversity of Maryland, Baltimore

Biodentin is one of 5 small molecule programs targeting Primary Teeth. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary TeethActive, not recruiting

Primary TeethPhase 3

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Primary Teeth

#DrugCompanyPhaseTrials

Mineral Trioxide Aggregate

JJordan University of Science and Technology

Phase 3

1 2

Biodentin

UUniversity of Maryland, Baltimore

Phase 3

1 3

Silver Diamine Fluoride

TThe University of Hong Kong

Preclinical

2 4

Neoputty MTA

OOctober University for Modern Sciences and Arts

Preclinical

1 5

Sodiumhexametaphosphate

MMinia University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalActive, not recruiting

Primary Teeth

NCT02298504

Clinical

Trials by Indication[1]

Primary Teeth1 trial

Vital Pulp Treatment in Primary Teeth

Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT02298504·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Biodentin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biodentin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biodentin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Maryland, Baltimore

Biodentin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Primary Teeth1 trial

References

Drug Info

Quick Facts

Related News